Biomarin Pharmaceutical Inc., of San Rafael, Calif., reported total revenues of $176.8 million for the third quarter, and non-GAAP net loss of $22.9 million, or 16 cents per share, besting consensus estimates, which has predicted a loss of 23 cents per share.